A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Haematologica. 2024 Mar 1;109(3):953-957. doi: 10.3324/haematol.2022.282246.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Letter

MeSH terms

  • Hodgkin Disease* / drug therapy
  • Humans
  • Lenalidomide

Substances

  • Lenalidomide